Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Dr. Inge Winter
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05603104CT.gov Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | — | Recruiting | — | — | — |
NCT05480150CT.gov Chinese Longitudinal and Systematic Study of Bioplar Disorder | — | Recruiting | — | — | — |
NCT04936126CT.gov Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression | — | Unknown | — | — | — |
NCT04521478CT.gov A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression | — | Completed | — | — | — |
NCT05840861CT.gov Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders | — | Unknown | — | — | — |
NCT04513912CT.gov A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy | — | Completed | — | — | — |
NCT04338321CT.gov A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder | — | Completed | — | — | — |
NCT04209166CT.gov A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features | — | Unknown | — | — | — |
NCT03321526CT.gov A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy | — | Completed | — | — | — |
NCT02720198CT.gov Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD | — | Completed | — | — | — |
Show 13 more trialsShow fewer
NCT01727726CT.gov A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial | — | Completed | — | — | — |
NCT01189318CT.gov Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder | — | Withdrawn | — | — | — |
NCT01725282CT.gov Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder | — | Completed | — | — | — |
NCT01357967CT.gov The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope | — | Unknown | — | — | — |
NCT01363310CT.gov The Quietude Study: Quetiapine Use for Agitated Depression | — | Terminated | — | — | — |
NCT01971203CT.gov Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat | — | Completed | — | — | — |
NCT00789854CT.gov Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients | — | Completed | — | — | — |
NCT00723970CT.gov Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression | — | Completed | — | — | — |
NCT00675896CT.gov A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome | — | Completed | — | — | — |
NCT00351910CT.gov Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder | — | Completed | — | — | — |
NCT00351169CT.gov Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder | — | Completed | — | — | — |
NCT03207438CT.gov Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression | — | Completed | — | — | — |
NCT00278941CT.gov Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Quetiapine (this asset) | Dr. Inge Winter | Approved | BB · 69 |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| Jnj-54135419 | Shanghai Mental Health Center | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Quetiapine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizoaffective Disorder | — | P4 | BBB · 76 |
| Bipolar Disorder | — | P4 | BBB · 74 |
| Substance Abuse | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Quetiapine in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/quetiapine-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →